3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
50
INDUSTRY
11
NIH
7
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
21
Lymphoma
10
Lymphoma, Mantle-Cell
4
Waldenstrom Macroglobulinemia
2
Recurrence
2
Mesothelioma, Malignant
2
Lymphoma, Follicular
2
Stomach Neoplasms
1
Sezary Syndrome
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Melphalan
5
Dexamethasone
5
Prednisone
4
Peripheral Blood Stem Cell Transplantation
3
Doxorubicin
3
Vincristine
2
Thalidomide
2
Lenalidomide
2
Filgrastim
2
Cyclophosphamide
2
valspodar
1
sargramostim
1
fludarabine phosphate
1
Vancomycin
1
Tazobactam
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiotherapy
1
Platelet Aggregation
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Moxifloxacin
1
Morphine
1
Methotrexate
1
Interferon-alpha
1
In Situ Hybridization, Fluorescence
1
Immunoenzyme Techniques
1
Gene Expression Profiling
1
Fenretinide
1
Etoposide
1
Dextromethorphan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Neoplasms, Plasma Cell
×
Bortezomib
×
Clear all
NCT00814541
2014-12-31
PAD. ICORG 05-01, V11
Cancer Trials Ireland
Phase 2
Completed
53 enrolled